Multilineage reconstitution of immunodeficient mice with human fetal liver cells transduced with the HS2-β-globin-GFP vector
| No. of experiments . | Target cells* . | Recipient (no. of cells injected/mouse)† . | % human cells‡ (% of human cells that are GFP+)2-153 . | |||
|---|---|---|---|---|---|---|
| CD45/71+ . | CD19/20+ . | CD15+ . | Glycophorin-A+ . | |||
| 3 | CD34+lin− | NOD/SCID | 19 ± 9 | 11 ± 5 | 4 ± 2 | 4 ± 2 |
| (15 ± 1.5 × 106) | (19 ± 4) | (12 ± 5) | (5 ± 2) | (3 ± 1) | ||
| n = 11 | ||||||
| 5 | CD34+38−lin− | NOD/SCID | 0.2 ± 0.1 | 0.05 ± 0.05 | 0.05 ± 0.05 | 0.1 ± 0.02 |
| (2 ± 0.4 × 106) | (4 ± 3) | (36 ± 19) | (4 ± 3) | (4 ± 3) | ||
| n = 4 | ||||||
| NOD/SCID-β2m−/− | 22 ± 9 | 14 ± 5 | 2 ± 1 | 3 ± 1 | ||
| (3.5 × 105) | (13 ± 4) | (12 ± 3) | (7 ± 3) | (6 ± 3) | ||
| n = 19 | ||||||
| No. of experiments . | Target cells* . | Recipient (no. of cells injected/mouse)† . | % human cells‡ (% of human cells that are GFP+)2-153 . | |||
|---|---|---|---|---|---|---|
| CD45/71+ . | CD19/20+ . | CD15+ . | Glycophorin-A+ . | |||
| 3 | CD34+lin− | NOD/SCID | 19 ± 9 | 11 ± 5 | 4 ± 2 | 4 ± 2 |
| (15 ± 1.5 × 106) | (19 ± 4) | (12 ± 5) | (5 ± 2) | (3 ± 1) | ||
| n = 11 | ||||||
| 5 | CD34+38−lin− | NOD/SCID | 0.2 ± 0.1 | 0.05 ± 0.05 | 0.05 ± 0.05 | 0.1 ± 0.02 |
| (2 ± 0.4 × 106) | (4 ± 3) | (36 ± 19) | (4 ± 3) | (4 ± 3) | ||
| n = 4 | ||||||
| NOD/SCID-β2m−/− | 22 ± 9 | 14 ± 5 | 2 ± 1 | 3 ± 1 | ||
| (3.5 × 105) | (13 ± 4) | (12 ± 3) | (7 ± 3) | (6 ± 3) | ||
| n = 19 | ||||||
Lin-depleted cells (with or without removal of CD38+ cells as indicated).
The number shown is the mean number of initial CD34+ or initial CD34+CD38− target cells from which the transduced cells injected (per mouse) were generated (± SEM).
Expressed as a percent of the total cells harvested from both femurs and both tibias of each mouse. Values shown are the mean ± SEM from the pooled data from all (n) mice.
Expressed as a percent of all human cells of the type analyzed. Values shown are the mean ± SEM from the pooled data from all (n) mice.